SCHEMBL5457843

SCHEMBL5457843

COc1cc(NC(=O)Nc2sc3cc(O)ccc3c2C(N)=O)cc(OC)c1OC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.44
MAPT P10636 3/20 0.44
POLB P06746 2/20 0.44
GFER P55789 1/20 0.44
CISD2 Q8N5K1 1/20 0.41
SAE1 Q9UBE0 1/20 0.41
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
LMNA P02545 1/20 0.40
TUBB4A P04350 2/20 0.40
TUBB P07437 2/20 0.40
TUBA3C P0DPH7 2/20 0.40
TUBA1B P68363 2/20 0.40
TUBA4A P68366 2/20 0.40
TUBB4B P68371 2/20 0.40
TUBB3 Q13509 2/20 0.40
TUBB2A Q13885 2/20 0.40
TUBB8 Q3ZCM7 2/20 0.40
TUBA3E Q6PEY2 2/20 0.40
TUBA1A Q71U36 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5453276 0.85 CSNK1D (0.46) ALDH1A1MAPTPOLBGFERCISD2
SCHEMBL5460392 0.85 RAB9A (0.49) ALDH1A1MAPTPOLBSAE1MEN1
SCHEMBL5447596 0.81 GAA (0.48) ALDH1A1MAPTMEN1KMT2ALMNA
SCHEMBL5451109 0.81 MEN1 (0.56) ALDH1A1MAPTMEN1KMT2ALMNA
SCHEMBL5460182 0.81 MEN1 (0.50) ALDH1A1MAPTPOLBMEN1KMT2A
SCHEMBL5458283 0.79 MEN1 (0.43) ALDH1A1MAPTMEN1KMT2ANPC1
SCHEMBL5456326 0.79 MEN1 (0.43) ALDH1A1MAPTMEN1KMT2ANPC1
SCHEMBL5459965 0.79 MDM2 (0.45) ALDH1A1MAPTMEN1KMT2ALMNA
SCHEMBL5455604 0.78 MAPT (0.48) ALDH1A1MAPTPOLBMEN1KMT2A
SCHEMBL17625474 0.78 CA12 (0.43) ALDH1A1MAPTMEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 ALDH1A1 1153/4885MAPT 21/4885POLB 404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.